Mol Psychiatry. 2009 Jan;14(1):10-7. doi: 10.1038/mp.2008.126. Epub 2008 Nov 11.
Genome-wide association studies (GWAS) have yielded a plethora of new findings in the past 3 years. By early 2009, GWAS on 47 samples of subjects with attention-deficit hyperactivity disorder, autism, bipolar disorder, major depressive disorder and schizophrenia will be completed. Taken together, these GWAS constitute the largest biological experiment ever conducted in psychiatry (59 000 independent cases and controls, 7700 family trios and >40 billion genotypes). We know that GWAS can work, and the question now is whether it will work for psychiatric disorders. In this review, we describe these studies, the Psychiatric GWAS Consortium for meta-analyses of these data, and provide a logical framework for interpretation of some of the conceivable outcomes.
在过去三年中，全基因组关联研究（GWAS）已产生了大量新发现。到2009年初，针对注意力缺陷多动障碍、自闭症、双相情感障碍、重度抑郁症和精神分裂症患者的47个样本的全基因组关联研究将完成。这些全基因组关联研究加在一起，构成了精神病学领域有史以来规模最大的生物学实验（59000个独立病例和对照、7700个三联体家庭以及超过400亿个基因型）。我们知道全基因组关联研究是可行的，现在的问题是它是否适用于精神疾病。在这篇综述中，我们描述了这些研究、用于对这些数据进行荟萃分析的精神病学全基因组关联研究联盟，并为解释一些可能的结果提供了一个逻辑框架。
